Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Study Finds Wide Variation in Prices of Generic Heart Failure Drugs

By JAMA Network Journals | November 23, 2016

A research letter published online by JAMA Internal Medicine found wide variations in pricing for generic heart failure (HF) drugs at retail pharmacies. The study is being released to coincide with its presentation at the American Heart Association’s Scientific Sessions 2016.

Recent increases in generic drug costs raise concerns about the effect on uninsured and underinsured patients who may be restricted to retail pharmacies within a geographic area. Among the uninsured are an estimated 7.3 million Americans with cardiovascular disease.

Paul J. Hauptman, M.D., of the Saint Louis University School of Medicine, Missouri, and coauthors evaluated retail pharmacy pricing for generic guideline-directed HF drugs in a two-state region around St. Louis. Pharmacies were contacted by phone and asked about the price – without insurance – for digoxin, lisinopril and carvedilol for 30- and 90-day supplies. The authors collected pricing data from 153 chain and 22 independent pharmacies.

Prices varied widely, according to the study. For example, a 30-day supply of digoxin plus higher-dose lisinopril and carvedilol varied from $12 to almost $398, with a median price of almost $71. A few pharmacies charged less than $25 for 30-day supplies and less than $100 for 90-day supplies for all three drugs. The most expensive drug was consistently digoxin, although it is the oldest cardiovascular medication available.

The primary driver of cost was the retail pharmacy and not other factors such as drug dose, therapy duration, pharmacy ownership or location, the authors report.

Limitations of the study include its sample, which was limited to just three drugs in one geographical area.

“In conclusion, generic drugs for HF show wide variability in pricing at the retail pharmacy level. The precise reasons for this, and the implications for adherence and subsequent clinical outcomes, require further study from both scientific and policy standpoints,” the article concludes.


Filed Under: Drug Discovery

 

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE